{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:23:39Z","timestamp":1792657419266,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:00:00Z","timestamp":1513382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00415-017-8708-4","type":"journal-article","created":{"date-parts":[[2017,12,16]],"date-time":"2017-12-16T00:10:22Z","timestamp":1513383022000},"page":"976-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["Transthyretin familial amyloid polyneuropathy: an update"],"prefix":"10.1007","volume":"265","author":[{"given":"Violaine","family":"Plante-Bordeneuve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,16]]},"reference":[{"key":"8708_CR1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"C Andrade","year":"1952","unstructured":"Andrade C (1952) A peculiar form of peripheral neuropathy; familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408\u2013427","journal-title":"Brain"},{"key":"8708_CR2","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66:2451\u20132466","journal-title":"J Am Coll Cardiol"},{"key":"8708_CR3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plant\u00e9-Bordeneuve","year":"2011","unstructured":"Plant\u00e9-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086\u20131097","journal-title":"Lancet Neurol"},{"issue":"12","key":"8708_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11940-016-0436-z","volume":"18","author":"P Kerschen","year":"2016","unstructured":"Kerschen P, Plant\u00e9-Bordeneuve V (2016) Current and future treatment approaches in transthyretin familial amyloid polyneuropathy. Curr Treat Options Neurol 18(12):53","journal-title":"Curr Treat Options Neurol"},{"key":"8708_CR5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","volume":"372","author":"CC Quarta","year":"2015","unstructured":"Quarta CC, Buxbaum JN, Shah AM et al (2015) The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 372:21\u201329","journal-title":"N Engl J Med"},{"key":"8708_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jns.12196","volume":"22","author":"G Liu","year":"2017","unstructured":"Liu G, Ni W, Wang H et al (2017) Clinical features of familial amyloid polyneuropathy carrying transthyretin mutations in four Chinese kindreds. J Peripher Nerv Syst 22:19\u201326","journal-title":"J Peripher Nerv Syst"},{"key":"8708_CR7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mgg3.231","volume":"4","author":"DR Jacobson","year":"2016","unstructured":"Jacobson DR, Alexander AA, Tagoe C et al (2016) The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa. Mol Genet Genomic Med 4:548\u2013556","journal-title":"Mol Genet Genomic Med"},{"key":"8708_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0593-4","author":"M Alves-Ferreira","year":"2017","unstructured":"Alves-Ferreira M, Coelho T, Santos D et al (2017) A trans-acting factor may modify age at onset in familial amyloid polyneuropathy ATTRV30M in Portugal. Mol Neurobiol. \n                        https:\/\/doi.org\/10.1007\/s12035-017-0593-4","journal-title":"Mol Neurobiol"},{"key":"8708_CR9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ejhg.2017.95","volume":"25","author":"A Iorio","year":"2017","unstructured":"Iorio A, De Lillo A, De Angelis F et al (2017) Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet 25:1055\u20131060","journal-title":"Eur J Hum Genet"},{"key":"8708_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/ejhg.2015.180","volume":"24","author":"D Santos","year":"2016","unstructured":"Santos D, Coelho T, Alves-Ferreira M et al (2016) Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M). Eur J Hum Genet 24:756\u2013760","journal-title":"Eur J Hum Genet"},{"key":"8708_CR11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/acn3.380","volume":"4","author":"D Santos","year":"2017","unstructured":"Santos D, Coelho T, Alves-Ferreira M et al (2017) Familial amyloid polyneuropathy in Portugal: new genes modulating age-at-onset. Ann Clin Transl Neurol 4:98\u2013105","journal-title":"Ann Clin Transl Neurol"},{"key":"8708_CR12","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.7150\/thno.14584","volume":"6","author":"SM Kurian","year":"2016","unstructured":"Kurian SM, Novais M, Whisenant T et al (2016) Peripheral blood cell gene expression diagnostic for identifying symptomatic transthyretin amyloidosis patients: male and female specific signatures. Theranostics 6:1792\u20131809","journal-title":"Theranostics"},{"key":"8708_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316657","author":"D Santos","year":"2017","unstructured":"Santos D, Santos MJ, Alves-Ferreira M et al (2017) mtDNA copy number associated with age of onset in familial amyloid polyneuropathy. J Neurol Neurosurg Psychiatry. \n                        https:\/\/doi.org\/10.1136\/jnnp-2017-316657","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"23","key":"8708_CR14","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hag\u00e8ge AA et al (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37(23):1826\u20131834","journal-title":"Eur Heart J"},{"key":"8708_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ana.24725","volume":"80","author":"AJ Loavenbruck","year":"2016","unstructured":"Loavenbruck AJ, Singer W, Mauermann ML et al (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80:401\u2013411","journal-title":"Ann Neurol"},{"key":"8708_CR16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MR et al (2016) A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry 87:620\u2013627","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8708_CR17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"L-L Mariani","year":"2015","unstructured":"Mariani L-L, Lozeron P, Th\u00e9audin M et al (2015) Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901\u2013916","journal-title":"Ann Neurol"},{"key":"8708_CR18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mus.25257","volume":"55","author":"T Coelho","year":"2017","unstructured":"Coelho T, Vinik A, Vinik EJ et al (2017) Clinical measures in transthyretin familial amyloid polyneuropathy. Muscle Nerve 55:323\u2013332","journal-title":"Muscle Nerve"},{"key":"8708_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mus.25563","volume":"56","author":"PJ Dyck","year":"2017","unstructured":"Dyck PJ, Kincaid JC, Dyck PJB et al (2017) Assessing mNIS+7Ionis and international neurologists\u2019 proficiency in a familial amyloidotic polyneuropathy trial. Muscle Nerve 56:901\u2013911","journal-title":"Muscle Nerve"},{"key":"8708_CR20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","volume":"87","author":"H Koike","year":"2016","unstructured":"Koike H, Ikeda S, Takahashi M et al (2016) Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology 87:2220\u20132229","journal-title":"Neurology"},{"key":"8708_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A et al (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88:457\u2013458","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8708_CR22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00415-014-7373-0","volume":"261","author":"V Plante-Bordeneuve","year":"2014","unstructured":"Plante-Bordeneuve V (2014) Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 261:1227\u20131233","journal-title":"J Neurol"},{"key":"8708_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L et al (2016) \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst JPNS 21:5\u20139","journal-title":"J Peripher Nerv Syst JPNS"},{"key":"8708_CR24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/brain\/awu344","volume":"138","author":"J Kollmer","year":"2015","unstructured":"Kollmer J, Hund E, Hornung B et al (2015) In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain 138:549\u2013562","journal-title":"Brain"},{"key":"8708_CR25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","volume":"89","author":"J Kollmer","year":"2017","unstructured":"Kollmer J, Sahm F, Hegenbart U et al (2017) Sural nerve injury in familial amyloid polyneuropathy: mR neurography vs clinicopathologic tools. Neurology 89:475\u2013484","journal-title":"Neurology"},{"key":"8708_CR26","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412","journal-title":"Circulation"},{"key":"8708_CR27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","volume":"82","author":"GJ Ebenezer","year":"2017","unstructured":"Ebenezer GJ, Liu Y, Judge DP et al (2017) Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol 82:44\u201356","journal-title":"Ann Neurol"},{"key":"8708_CR28","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1212\/WNL.0000000000004016","volume":"88","author":"T Masuda","year":"2017","unstructured":"Masuda T, Ueda M, Suenaga G et al (2017) Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy. Neurology 88:2192\u20132197","journal-title":"Neurology"},{"key":"8708_CR29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.24914","volume":"81","author":"Y Misumi","year":"2017","unstructured":"Misumi Y, Ueda M, Yamashita T et al (2017) Novel screening for transthyretin amyloidosis by using fat ultrasonography. Ann Neurol 81:604\u2013608","journal-title":"Ann Neurol"},{"key":"8708_CR30","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","volume":"127","author":"J Castro","year":"2016","unstructured":"Castro J, Miranda B, Castro I et al (2016) The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Clin Neurophysiol 127:2222\u20132227","journal-title":"Clin Neurophysiol"},{"key":"8708_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","volume":"21","author":"A Carvalho","year":"2015","unstructured":"Carvalho A, Rocha A, Lobato L (2015) Liver transplantation in transthyretin amyloidosis: issues and challenges. Liver Transpl 21:282\u2013292","journal-title":"Liver Transpl"},{"key":"8708_CR32","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"B-G Ericzon","year":"2015","unstructured":"Ericzon B-G, Wilczek HE, Larsson M et al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99:1847\u20131854","journal-title":"Transplantation"},{"key":"8708_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","volume":"86","author":"LF Maia","year":"2015","unstructured":"Maia LF, Magalh\u00e3es R, Freitas J et al (2015) CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 86:159\u2013167","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8708_CR34","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","volume":"87","author":"Y Sekijima","year":"2016","unstructured":"Sekijima Y, Yazaki M, Oguchi K et al (2016) Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology 87:773\u2013781","journal-title":"Neurology"},{"key":"8708_CR35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/13506129.2017.1335639","volume":"24","author":"V Freitas Castro","year":"2017","unstructured":"Freitas Castro V, Nascimento Alves P, Franco AC et al (2017) Cognitive impairment in liver transplanted patients with transthyretin-related hereditary amyloid polyneuropathy. Amyloid 24:110\u2013114","journal-title":"Amyloid"},{"key":"8708_CR36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","volume":"299","author":"P Hammarstr\u00f6m","year":"2003","unstructured":"Hammarstr\u00f6m P, Wiseman RL, Powers ET, Kelly JW (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 299:713\u2013716","journal-title":"Science"},{"key":"8708_CR37","doi-asserted-by":"crossref","first-page":"9992","DOI":"10.1073\/pnas.1300761110","volume":"110","author":"SC Penchala","year":"2013","unstructured":"Penchala SC, Connelly S, Wang Y et al (2013) AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA 110:9992\u20139997","journal-title":"Proc Natl Acad Sci USA"},{"key":"8708_CR38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13:236\u2013249","journal-title":"Amyloid"},{"key":"8708_CR39","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310:2658\u20132667","journal-title":"JAMA"},{"key":"8708_CR40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","volume":"22","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y, Tojo K, Morita H et al (2015) Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 22:79\u201383","journal-title":"Amyloid"},{"key":"8708_CR41","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, Devit M et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109:9629\u20139634","journal-title":"Proc Natl Acad Sci USA"},{"key":"8708_CR42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785\u2013792","journal-title":"Neurology"},{"key":"8708_CR43","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","volume":"260","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maia LF, da Silva AM et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802\u20132814","journal-title":"J Neurol"},{"key":"8708_CR44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B et al (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24:194\u2013204","journal-title":"Amyloid"},{"key":"8708_CR45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","volume":"23","author":"M Waddington Cruz","year":"2016","unstructured":"Waddington Cruz M, Amass L, Keohane D et al (2016) Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 23:178\u2013183","journal-title":"Amyloid"},{"key":"8708_CR46","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00415-016-8064-9","volume":"263","author":"A Cortese","year":"2016","unstructured":"Cortese A, Vita G, Luigetti M et al (2016) Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263:916\u2013924","journal-title":"J Neurol"},{"key":"8708_CR47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plant\u00e9-Bordeneuve","year":"2017","unstructured":"Plant\u00e9-Bordeneuve V, Gorram F, Salhi H et al (2017) Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol 264:268\u2013276","journal-title":"J Neurol"},{"key":"8708_CR48","doi-asserted-by":"publisher","unstructured":"Maurer MS, Elliott P, Merlini G et al (2017) Design and rationale of the phase 3 ATTR-ACT Clinical Trial (tafamidis in transthyretin cardiomyopathy clinical trial). Circ Heart Fail 10(6). \n                        https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003815","DOI":"10.1161\/CIRCHEARTFAILURE.116.003815"},{"key":"8708_CR49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/mus.20503","volume":"33","author":"MD Benson","year":"2006","unstructured":"Benson MD, Kluve-Beckerman B, Zeldenrust SR et al (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33:609\u2013618","journal-title":"Muscle Nerve"},{"key":"8708_CR50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD et al (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid 23:148\u2013157","journal-title":"Amyloid"},{"key":"8708_CR51","unstructured":"Ionis pharmaceuticals (2017) Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTRRx) Meets Both Primary Endpoints. Press release 2017 May 15th and November 2nd"},{"key":"8708_CR52","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love KT, Mahon KP, Levins CG et al (2010) Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 107:1864\u20131869","journal-title":"Proc Natl Acad Sci USA"},{"key":"8708_CR53","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"T Coelho","year":"2013","unstructured":"Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819\u2013829","journal-title":"N Engl J Med"},{"key":"8708_CR54","unstructured":"Alnylam pharmaceuticals (2017) Apollo-Patisiran phase 3 study: Topline results. Press release, 2017 November 2"},{"key":"8708_CR55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC et al (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468:93\u201397","journal-title":"Nature"},{"key":"8708_CR56","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC et al (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373:1106\u20131114","journal-title":"N Engl J Med"},{"key":"8708_CR57","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbapap.2014.08.016","volume":"1844","author":"E Genst De","year":"2014","unstructured":"De Genst E, Messer A, Dobson CM (2014) Antibodies and protein misfolding: from structural research tools to therapeutic strategies. Biochim Biophys Acta 1844:1907\u20131919","journal-title":"Biochim Biophys Acta"},{"key":"8708_CR58","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","volume":"23","author":"JN Higaki","year":"2016","unstructured":"Higaki JN, Chakrabartty A, Galant NJ et al (2016) Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 23:86\u201397","journal-title":"Amyloid"},{"key":"8708_CR59","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mus.25210","volume":"54","author":"HH-J Schmidt","year":"2016","unstructured":"Schmidt HH-J, Barroso F, Gonz\u00e1lez-Duarte A et al (2016) Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle Nerve 54:353\u2013360","journal-title":"Muscle Nerve"},{"key":"8708_CR60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/13506129.2017.1293515","volume":"24","author":"F Gorram","year":"2017","unstructured":"Gorram F, Alarcon F, Perdry H et al (2017) Refine penetrance estimates in the main pathogenic variants of transthyretin hereditary (familial) amyloid polyneuropathy (TTR-FAP) using a new non-parametric approach (NPSE). Amyloid 24:115\u2013116","journal-title":"Amyloid"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8708-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8708-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,30]],"date-time":"2018-03-30T08:26:13Z","timestamp":1522398373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8708-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["8708"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8708-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,16]]}}}